Results from the first-in-human phase I trials of recombinant human Interleukin 15 (rhIL-15) administered as a daily 30 minute intravenous infusion (IVB) for 12 consecutive days or as continuous intravenous infusion (CIV) for 240 hours in patients with refractory metastatic cancers
Journal article published in 2014 by
Kevin C. Conlon,
Enrico Lugli,
Steven A. Rosenberg,
John C. Morris,
Thomas Fleisher,
Hugh Welles 
,
Sigrid Dubois,
Liyanage Perera,
Carolyn Goldman,
Bonita Bryant
,
Sigrid Dubois,
Liyanage Perera,
Carolyn Goldman,
Bonita Bryant
